Homepage
Dosing & Administration
Patients' convenience

Patients' convenience

Elderly couple holding hands, dressed as fighters.

Cutaquig® gives patients the flexibility to fit treatment around their individual lifestyle

Cutaquig® can be administered safely at flexible infusion regimens1

Increasing infusion rate up
to 67.5 mL/hr/site decreased infusion duration by >57% ¹ Dosing every other week demonstrated equivalency to IgG trough levels with weekly dosing ¹ Increasing infusion volume per site up to 100 mL/site resulted in a >30% reduction of injection sites ¹ ¹ A phase 3 study monitoring the safety, tolerability and efficacy of cutaquig® at modified dosing regimendemonstrated that:
Increasing infusion volume per site up to 100 mL/site resulted in a >30% reduction of injection sites ¹ Increasing infusion rate up
to 67.5 mL/hr/site decreased infusion duration by >57% ¹ Dosing every other week demonstrated equivalency to IgG trough levels with weekly dosing ¹ A phase 3 study monitoring the safety, tolerability and efficacy of cutaquig® at modified dosing regimen demonstrated that: ¹

*Increased infusion volume per site up to 100 mL/site, increased infusion rate up to 67.5 mL/hr/site or dosing every other week. The majority of patients found the new infusion regimens* to be better or somewhat better than their previous regimens and reported that switching to SCIg 16.5% was easy ¹
The majority of patients found the new infusion regimens* to be better or somewhat better than their previous regimens and reported that switching to SCIg 16.5% was easy ¹ *Increased infusion volume per site up to 100 mL/site, increased infusion rate up to 67.5 mL/hr/site or dosing every other week.
Cutaquig® can be stored at room temperature (up to 25°C without refrigeration) for up to 9 months*, giving patients more flexibility ²
Cutaquig® can be stored at room temperature (up to 25°C without refrigeration) for up to 9 months*, giving patients more flexibility ²
A range of different vial sizes (1 to 8 grams) is available for flexible dose adjustments to meet individual needs ¹
A range of different vial sizes (1 to 8 grams) is available1 for flexible dose adjustments to meet individual needs
As patients’ needs constantly evolve, having corresponding intravenous immunoglobulin (IVIg) and SCIg formulations helps easy transitions from one administration method to another
As patients’ needs constantly evolve, having corresponding intravenous immunoglobulin (IVIg) and SCIg formulations helps easy transitions from one administration method to another

Cutaquig® can be self-administered at home

Cutaquig® is a SCIg, removing the need for frequent travel to infusion clinics or hospitals for IgG administration ³
Cutaquig® is a SCIg, removing the need for frequent travel to infusion clinics or hospitals for IgG administration ³
Cutaquig®’s self-administration supports patients to independently take control of their treatment ⁴
Cutaquig®’s self-administration supports patients to independently take control of their treatment ⁴
*Cutaquig® can be stored at normal room temperature (up to 25°C, so patients don’t need to store it in the refrigerator) for up to 9 months and must then be discarded. However, for long-term storage, cutaquig® should be stored in a refrigerator at 2°C – 8°C. Before use, cutaquig® should be brought to room or body temperature. ² Cutaquig® can improve patients’ quality of life; in the pivotal trial, an average of only 2.63 days were missed from school or work per person-year ⁴
Cutaquig® can improve patients’ quality of life; in the pivotal trial, an average of only 2.63 days were missed from school or work per person-year ⁴ *Cutaquig® can be stored at normal room temperature (up to 25°C, so patients don’t need to store it in the refrigerator) for up to 9 months and must then be discarded. However, for long-term storage, cutaquig® should be stored in a refrigerator at 2°C – 8°C. Before use, cutaquig® should be brought to room or body temperature. ²

References:

  1. Gupta S, et al. Subcutaneous Immunoglobulin 16.5 (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens. J Clin Immunol. 2023; 43(6):1414-1425.

  2. Cutaquig® Summary of Product Characteristics. November 2023.

  3. Gardulf, A. Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm®. Immunotherapy, 2016. 8(5):633-647.

  4. Kobayashi, R.H., et al., Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (octanorm [cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol, 2019. 10:40.

This is an international website for cutaquig® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).

If you wish to contact Octapharma please use the contact form on our corporate website www.octapharma.com.

Legal Statement

Data Privacy Statement

© 2025 Octapharma AG